Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024
November 13, 2023 16:05 ET
|
Beyond Air™
Provides fiscal year 2025 revenue guidance of $12 - $16 million US pilot trial of LungFit® PRO to treat viral community acquired pneumonia (VCAP) underway with data expected mid-calendar 2024 Beyond...
Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
November 03, 2023 12:00 ET
|
Beyond Air™
First-in-human Phase 1 study demonstrates early clinical proof of concept Positive clinical biomarker data demonstrate evidence of immune system activation and the translation of the immunogenic...
Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast
October 19, 2023 16:05 ET
|
Beyond Air™
GARDEN CITY, N.Y., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on...
Beyond Air® To Participate in the Truist Securities BioPharma Symposium
October 17, 2023 16:05 ET
|
Beyond Air™
GARDEN CITY, N.Y., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on...
Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice
October 17, 2023 07:30 ET
|
Beyond Air™
UNO therapy results in a more immunogenic tumor microenvironment (TME) as well as a systemic response that overcomes anti-PD-1 resistance First-in-human Phase 1 clinical study is ongoing with...
Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 16, 2023 07:30 ET
|
Beyond Air™
50,000 or 100,000 ppm UNO alone or in combination with anti-mCTLA-4 more than tripled antigen specific central memory T-cell response versus anti-mCTLA-4 alone Pooled analysis of combination...
Beyond Air® Receives Innovative Technology Contract from Vizient for LungFit®PH
October 16, 2023 07:00 ET
|
Beyond Air™
GARDEN CITY, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...
Beyond Cancer™ Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 04, 2023 07:30 ET
|
Beyond Air™
GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric...
Beyond Air® To Participate in the Roth MKM 2023 Healthcare Opportunities Conference
October 02, 2023 16:05 ET
|
Beyond Air™
GARDEN CITY, N.Y., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on...
Beyond Cancer™ to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting
September 27, 2023 09:00 ET
|
Beyond Air™
GARDEN CITY, N.Y. and HAMILTON, Bermuda, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd. (the “Company”), an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high...